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background
 
CD40 ligand is expressed on platelets and released from them on activation. We inves-
tigated the predictive value of soluble CD40 ligand as a marker for clinical outcome and
the therapeutic effect of glycoprotein IIb/IIIa receptor inhibition in patients with acute
coronary syndromes.
 
methods
 
Serum levels of soluble CD40 ligand were measured in 1088 patients with acute cor-
onary syndromes who had previously been enrolled in a randomized trial comparing
abciximab with placebo before coronary angioplasty and in 626 patients with acute
chest pain.
 
results
 
The levels of soluble CD40 ligand were elevated (above 5.0 µg per liter) in 221 patients
with acute coronary syndromes (40.6 percent). Among patients receiving placebo, elevat-
ed soluble CD40 ligand levels indicated a significantly increased risk of death or nonfatal
myocardial infarction during six months of follow-up (adjusted hazard ratio as com-
pared with patients with low levels of the ligand [≤5.0 µg per liter], 2.71; 95 percent con-
fidence interval, 1.51 to 5.35; P=0.001). The prognostic value of this marker was val-
idated in the patients with chest pain, among whom elevated soluble CD40 ligand levels
identified those with acute coronary syndromes who were at high risk for death or non-
fatal myocardial infarction (adjusted hazard ratio as compared with those with low levels
of the ligand, 6.65; 95 percent confidence interval, 3.18 to 13.89; P<0.001). The increased
risk in patients with elevated soluble CD40 ligand levels was significantly reduced by
treatment with abciximab (adjusted hazard ratio as compared with those receiving pla-
cebo, 0.37; 95 percent confidence interval, 0.20 to 0.68; P=0.001), whereas there was
no significant treatment effect of abciximab in patients with low levels of soluble CD40
ligand.
 
conclusions
 
In patients with unstable coronary artery disease, elevation of soluble CD40 ligand
levels indicated an increased risk of cardiovascular events. Elevation of soluble CD40
ligand identifies a subgroup of patients at high risk who are likely to benefit from an-
tiplatelet treatment with abciximab.
abstract
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stablishing the correct diagno
 
-
sis and initiating the appropriate treatment
in patients with acute coronary syndromes
who do not have ST-segment elevation can be chal-
lenging. Sensitive and specific markers of myocar-
dial-cell necrosis, notably cardiac troponins, have
become valuable tools in the evaluation of patients
with acute coronary syndromes.
 
1
 
 However, troponins
are not actively involved in the pathophysiology of
acute coronary syndromes and, instead, represent a
surrogate marker for the formation of fragile throm-
bi.
 
2-4
 
 Markers of platelet activation that can be used
to identify disease activity even before myocardial
necrosis occurs may provide important supplemen-
tary information for the diagnostic and therapeutic
stratification of patients with acute coronary syn-
dromes.
Increasing evidence suggests that CD40 ligand
plays an important part in disease progression and
plaque destabilization.
 
5,6
 
 The CD40–CD40 lig-
and system is widely distributed on a variety of leu-
kocytic and nonleukocytic cells, including endo-
thelial and smooth-muscle cells,
 
7
 
 and on activated
platelets.
 
8
 
 CD40 ligand also occurs in a soluble form
that is fully active biologically, termed soluble CD40
ligand,
 
9
 
 which is shed from stimulated lympho-
cytes and is actively released after platelet stimula-
tion.
 
10,11
 
 Soluble CD40 ligand is proinflammatory
for endothelial cells and promotes coagulation by
inducing expression of tissue factor on monocytes
 
12
 
and endothelial cells.
 
13
 
 Moreover, soluble CD40 lig-
and contains a KGD sequence,
 
9
 
 a known binding
motif that is specific for the major platelet integrin
 
a
 
IIb
 
b
 
3.
 
14
 
 Indeed, CD40 ligand has been demon-
strated to be an 
 
a
 
IIb
 
b
 
3 (glycoprotein IIb/IIIa) ligand
and a platelet agonist and to be necessary for the
stability of arterial thrombi.
 
15
 
These data suggest that soluble CD40 ligand
plays an important part in the pathophysiology of
acute coronary syndromes. Apparently healthy wom-
en with increased plasma levels of soluble CD40
ligand have been shown to be at increased risk for
cardiovascular events.
 
16
 
 Elevation of soluble CD40
ligand levels is detectable in the serum of patients
with acute coronary syndromes.
 
17
 
 Accordingly, we
investigated the predictive value of serum levels of
soluble CD40 ligand with respect to cardiac events
and the effects of the glycoprotein IIb/IIIa inhibi-
tor abciximab in patients with acute coronary syn-
dromes who were enrolled in the c7E3 Fab Anti-
platelet Therapy in Unstable Refractory Angina
(CAPTURE) study.
 
18
 
patients with acute coronary syndromes
 
The CAPTURE trial enrolled 1265 patients with
acute coronary syndromes who had recurrent chest
pain at rest in association with electrocardiographic
changes. Before randomization, all patients were
documented by coronary angiography to have sub-
stantial coronary artery disease, with stenosis of at
least 70 percent of the coronary-artery diameter at
a culprit lesion that was suitable for angioplasty. The
patients were randomly assigned to receive abcix-
imab or placebo, and coronary angioplasty was
scheduled 18 to 24 hours after the study treatment
was begun. The combined primary end point was
death or nonfatal myocardial infarction during 30
days and 6 months of follow-up.
 
18
 
patients with acute chest pain
 
A separate validation sample consisted of 626 con-
secutive patients (465 men and 161 women; mean
[
 
±
 
SD] age, 62
 
±
 
12 years) who presented with acute
chest pain lasting less than 12 hours (mean, 5.1
 
±
 
3.6)
and had no ST-segment elevation on electrocardi-
ography. The presence of coronary artery disease
was documented by one of the following criteria:
electrocardiographic evidence of myocardial ische-
mia (new ST-segment changes or T-wave inversions)
or a history of coronary heart disease (myocardial
infarction, coronary revascularization, a positive ex-
ercise stress test, or stenosis of more than 50 percent
of the luminal diameter of a major coronary artery
on a previous angiogram). All patients were followed
for 30 days for the occurrence of death or nonfatal
myocardial infarction. The study protocol was ap-
proved by the ethics committee of the Hamburg
Medical Board, and written informed consent was
obtained from each patient.
 
biochemical analysis
 
Soluble CD40 ligand, soluble P-selectin, high-sen-
sitivity tumor necrosis factor 
 
a
 
, and soluble intra-
cellular adhesion molecule 1 were measured by en-
zyme-linked immunosorbent assay (R&D Systems).
Troponin T was measured with an electrochemilu-
minescence enzyme-linked immunosorbent assay
(Elecsys 2010, Roche Diagnostics), and C-reactive
protein was measured by nephelometry (Behring
BN II Nephelometer, Dade–Behring).
 
in vivo platelet activation
 
In a subgroup of 161 patients with chest pain (131
patients with acute coronary syndromes, 20 patients
e methods
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with stable coronary heart disease, and 10 patients
without coronary heart disease), platelet activation
was assessed by flow cytometry with the use of phy-
coerythrin-conjugated glycoprotein IIb–specific
monoclonal antibodies (CD41, Dako) and fluores-
cein isothiocyanate (FITC)–conjugated, P-selectin–
specific monoclonal antibodies (BD Pharmingen).
Circulating monocyte–platelet aggregates were
stained with FITC-conjugated, glycoprotein IIIa–
specific monoclonal antibody (CD61, Dako) and
phycoerythrin-conjugated monoclonal antibodies
against CD14 (BD Pharmingen). Monocyte–platelet
aggregates were defined as monocytes positive for
glycoprotein IIIa, and values are expressed as the
percentage of aggregated monocytes.
 
19
 
statistical analysis
 
To distinguish between patients with different de-
grees of cardiac risk, an exploratory data analysis
was chosen. The Cox proportional-hazards regres-
sion model was used to estimate the relative risk of
cardiovascular events, and patients were catego-
rized according to quintiles of soluble CD40 ligand
levels.
 
20
 
 We analyzed the effect of base-line charac-
teristics and other biochemical markers on any ob-
served associations between soluble CD40 ligand
levels and cardiovascular events, using stepwise Cox
proportional-hazards models (with a value of
P=0.10 necessary to enter a variable into the model).
All results for continuous variables are expressed
as means 
 
±
 
SD. Comparisons between groups were
analyzed with a two-sided t-test. Categorical vari-
ables were compared by the Pearson chi-square test.
Post hoc analysis was performed by using the Cox
proportional-hazards regression model, with the
quintile for soluble CD40 ligand as a categorical var-
iable and the quintile group with the lowest levels
of soluble CD40 ligand serving as the reference
group. P values under 0.05 were considered to indi-
cate statistical significance. All analyses were per-
formed with SPSS software (version 11.0).
 
patients with acute coronary syndromes
 
Base-line samples were available for 1088 of the
1265 patients with acute coronary syndromes (86
percent).
 
21
 
 The level of soluble CD40 ligand did
not correlate with measured levels of troponin T
(r=0.14) or C-reactive protein (r=0.11).
 
Soluble CD40 Ligand and Cardiovascular Risk
 
The 544 patients in the placebo group of the study
were classified according to their measured levels
of soluble CD40 ligand at base line, as follows: 100
in the first quintile (<1.93 µg per liter), 102 in the
second quintile (1.93 to 3.50 µg per liter), 121 in
the third quintile (3.51 to 5.00 µg per liter), 115 in
the fourth quintile (5.01 to 6.30 µg per liter), and
106 in the fifth quintile (>6.30 µg per liter). For the
initial 24-hour period before coronary angioplasty,
the incidence of the combined end point of death
or nonfatal myocardial infarction did not differ sig-
nificantly among patients in these groups (P=0.13).
For the later follow-up times (72 hours, 30 days, and
6 months), the rates of events were significantly
higher in both the fourth quintile (P=0.01, P=0.02,
and P=0.003, respectively) and the fifth quintile (P=
0.009, P=0.005, and P=0.002, respectively) (Fig. 1).
Accordingly, the patient sample was divided
into two groups with soluble CD40 ligand levels of
greater than 5.0 µg per liter or 5.0 µg per liter or less;
221 patients (40.6 percent) were thus classified as
having high levels of soluble CD40 ligand and 323
patients as having low levels. There were no signif-
icant differences in the base-line characteristics of
the two groups (Table 1). The incidence of death or
nonfatal myocardial infarction was higher in pa-
tients who had elevated soluble CD40 ligand levels
results
 
Figure 1. Association between Soluble CD40 Ligand Levels and the Rate of 
Cardiac Events (Death or Nonfatal Myocardial Infarction) at 24 Hours, 72 Hours, 
30 Days, and 6 Months among 544 Patients Receiving Placebo.
 
The patients were divided into quintiles according to the serum level of solu-
ble CD40 ligand, as follows: first quintile, below 1.93 µg per liter; second quin-
tile, 1.93 to 3.50 µg per liter; third quintile, 3.51 to 5.00 µg per liter; fourth quintile, 
5.01 to 6.30 µg per liter; and fifth quintile, above 6.30 µg per liter. P values are 
for trend at each time point.
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before coronary angioplasty (4.1 percent, vs. 0.9
percent among patients with low levels; P=0.02),
after 72 hours, a period during which coronary an-
gioplasty was performed in all patients (13.1 percent
vs. 4.3 percent, P<0.001), after 30 days (14.5 percent
vs. 5.3 percent, P<0.001), and after 6 months (18.6
percent vs. 7.1 percent, P<0.001) (Fig. 2 and 3). The
predictive value of soluble CD40 ligand was inde-
pendent of the presence or absence of myocardial
necrosis as evidenced by the troponin T level (Ta-
ble 2). Among the patients who were negative for
troponin T, high levels of soluble CD40 ligand iden-
tified a subgroup with an increased risk of cardiac
events (13.6 percent) that was not significantly dif-
ferent from the risk in troponin T–positive patients
(14.0 percent, P=1.00).
 
Abciximab Treatment and Soluble CD40 Ligand
 
Among patients in the first three quintiles for solu-
ble CD40 ligand, no significant differences in cardi-
ac risk were observed between those receiving place-
bo and those receiving abciximab (Fig. 4). Among
patients in the highest two quintiles, a significant
reduction in cardiac risk, which did not differ be-
tween the two quintiles, was documented for those
receiving abciximab. The abrupt change in the haz-
ard ratio from 1.12 in the third quintile to 0.35 in the
fourth suggests a threshold level of benefit in this
range of soluble CD40 ligand levels. Accordingly,
curves for the incidence of death or nonfatal myo-
cardial infarction were generated with a threshold
level of 5.0 µg of soluble CD40 per liter. Among pa-
tients with low levels of soluble CD40 ligand, no
significant difference in incidence was observed be-
tween patients receiving abciximab and those receiv-
ing placebo (1.2 percent vs. 0.9 percent at 24 hours,
and 3.8 percent vs. 4.3 percent at 72 hours) (Fig. 2).
In contrast, the rates of death or nonfatal myocardial
infarction were significantly higher among patients
with high levels of soluble CD40 ligand who were
receiving placebo and were effectively reduced by
treatment with abciximab before coronary angio-
plasty (hazard ratio, 0.12; 95 percent confidence
interval, 0.01 to 0.92; P=0.01); the same was true for
angioplasty-related events (hazard ratio, 0.19; 95
percent confidence interval, 0.08 to 0.49; P<0.001).
This benefit persisted during six months of follow-
up (hazard ratio, 0.37; 95 percent confidence inter-
val, 0.20 to 0.68; P=0.001) (Fig. 3). Among tropo-
nin T–negative patients, high levels of soluble CD40
ligand identified a subgroup whose risk of cardiac
events was significantly reduced by treatment with
abciximab (5.5 percent, vs. 13.6 percent for those
receiving placebo; P=0.03).
 
patients with acute chest pain
 
Of the 626 patients with acute chest pain, 308 had
acute coronary syndromes (117 of whom had myo-
cardial infarction without ST-segment elevation). Of
the remaining patients stable angina was diagnosed
in 91, pulmonary embolism in 10, congestive heart
failure in 11, and myocarditis in 7. No evidence of
heart disease was found in 199. Soluble CD40 lig-
and levels were significantly higher in the 308 pa-
tients with acute coronary syndromes (mean, 4.53 µg
per liter; 95 percent confidence interval, 3.19 to 5.87)
than in patients with stable angina (mean, 2.41 µg
per liter; 95 percent confidence interval, 1.99 to 3.52;
P<0.001) and patients without evidence of heart dis-
ease (mean, 1.57 µg per liter; 95 percent confidence
interval, 0.88 to 1.76; P<0.001). The 97.5th percen-
tile for the soluble CD40 ligand level in patients
without evidence of heart disease was 4.7 µg per liter,
and the 99th percentile was 6.2 µg per liter. Soluble
 
* Plus–minus values are means ±SD.
 
Table 1. Base-Line Characteristics of Patients with Acute Coronary Syndromes 
Who Were Randomly Assigned to the Placebo Group, According to the Level 
of Soluble CD40 Ligand.*
Characteristic
Low 
(≤5.0 µg per liter)
High 
(>5.0 µg per liter) P Value
 
No. of patients 323 221
Male sex (%) 73.3 70.2 0.49
Mean age (yr) 60.5±9.9 62.3±10.5 0.72
Clinical history (%)
Angina >7 days previously
Myocardial infarction 
≤30 days previously
Myocardial infarction 
>30 days previously
Coronary angioplasty
Coronary-artery bypass 
surgery
57.5
16.9
19.5
19.1
3.5
54.6
19.2
21.0
15.9
3.4
0.59
0.45
0.82
0.32
1.00
Risk factors (%)
Diabetes
Hypercholesterolemia
Hypertension
Current smoking
12.1
32.5
39.3
40.9
9.6
33.6
34.5
42.1
0.73
0.86
0.47
0.68
Medication before 
enrollment (%)
Aspirin
Intravenous heparin
Intravenous nitrates
Beta-blockers
98.1
99.2
98.8
65.0
97.9
98.6
99.7
61.4
1.00
0.95
1.00
0.79
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CD40 ligand levels did not correlate with markers
of necrosis (troponin T levels), markers of inflam-
mation (levels of C-reactive protein and tumor ne-
crosis factor 
 
a
 
), or adhesion molecules (soluble in-
tracellular adhesion molecule 1).
Among the 308 patients with acute coronary
syndromes, 43.5 percent had soluble CD40 ligand
levels above the 97.5th-percentile upper reference
limit. When the prespecified threshold value for
soluble CD40 ligand of 5.0 µg per liter was used, pa-
tients with elevated levels were at significantly high-
er risk for death or nonfatal myocardial infarction
than those with lower levels (adjusted hazard ra-
tio, 3.00; 95 percent confidence interval, 1.35 to 6.71;
P=0.009). Among the entire heterogeneous popu-
lation of 626 patients with chest pain, the threshold
value of 5.0 µg per liter also reliably identified pa-
tients who were at highest risk for death or nonfa-
tal myocardial infarction (adjusted hazard ratio,
6.65; 95 percent confidence interval, 3.18 to 13.89;
P<0.001).
 
association of soluble cd40 ligand levels 
with platelet activation
 
In a subgroup of 161 patients with chest pain, we
observed a strong correlation between platelet ac-
tivation, as evidenced by the percentage of mono-
cytes that were aggregated with platelets (mono-
cyte–platelet aggregates), and soluble CD40 ligand
levels (r=0.75, P<0.001) (Fig. 5). Similar results
were obtained for P-selectin expression on platelets
(P<0.001; data not shown). Patients were divided
into three roughly equal groups according to their
measured levels of soluble CD40 ligand: 55 with
levels below 2.5 µg per liter, 50 with levels of 2.5 to
4.5 µg per liter, and 56 with levels above 4.5 µg per
liter. For patients in the group with the lowest lev-
els, the mean percentage of monocyte–platelet
aggregates was 11.3
 
±
 
6.1 percent. For those in the
other two groups, platelet activation was signifi-
cantly higher, with monocyte–platelet aggregates
of 22.3
 
±
 
8.9 percent (P<0.001) and 34.1
 
±
 
15.6 per-
cent (P<0.001), respectively.
The present study demonstrates that soluble CD40
ligand is a powerful biochemical marker of inflam-
matory thrombotic activity in patients with acute
coronary syndromes. Elevated levels of soluble CD40
discussion
 
Figure 2. Kaplan–Meier Curves Showing the Cumulative Incidence of Death 
or Nonfatal Myocardial Infarction during 72 Hours of Follow-up, According to 
the Base-Line Level of Soluble CD40 Ligand in the Placebo Group (544 Pa-
tients) and the Abciximab Group (544 Patients).
 
High levels of soluble CD40 ligand were defined as levels greater than 5.0 µg 
per liter, and low levels as 5.0 µg per liter or less.
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Figure 3. Kaplan–Meier Curves Showing the Cumulative Incidence of Death 
or Nonfatal Myocardial Infarction during Six Months of Follow-up, According 
to the Base-Line Level of Soluble CD40 Ligand in the Placebo Group (544 Pa-
tients) and the Abciximab Group (544 Patients).
 
High levels of soluble CD40 ligand were defined as levels greater than 5.0 µg 
per liter, and low levels as 5.0 µg per liter or less.
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ligand reliably identify the subgroup of patients with
acute coronary syndromes who are at highest risk
for cardiac events and who receive substantial ben-
efit from treatment with the glycoprotein IIb/IIIa re-
ceptor antagonist abciximab. Thus, soluble CD40
ligand not only contributes importantly to the patho-
physiology of acute coronary syndromes but also
represents a reliable and powerful clinical marker
for use in identifying patients with high-risk athero-
sclerotic lesions, coronary thrombosis, or both.
 
15,22
 
Soluble CD40 ligand was a powerful prognostic
marker that provided information beyond the evi-
dence provided by troponin T, the inflammatory
marker C-reactive protein, tumor necrosis factor
 
a
 
, and the soluble intracellular adhesion molecule
1. In a multivariate Cox regression model, troponin
T, C-reactive protein, and soluble CD40 ligand pro-
vided independent and incremental prognostic in-
formation (Table 2). Troponins are markers of my-
ocardial necrosis; they are not actively involved in
the pathophysiology of acute coronary syndromes
but, rather, are surrogate markers for the formation
of fragile thrombi.
 
2-4
 
 Postmortem studies in pa-
tients with acute coronary syndromes identified ero-
sion or rupture of the fibrous cap of the atheroscle-
rotic plaque, leading to platelet activation, as the
underlying pathophysiological feature.
 
5,6,23-25
 
 Cor-
onary arterial thromboembolism, with altered mi-
crovascular perfusion and necrosis, is an integral
part of acute coronary syndromes.
 
3,4
 
 Accordingly,
sensitive markers for the detection of minor myo-
cardial injury, notably troponins, serve as surro-
gate markers for arterial thromboembolism orig-
inating from an active thrombotic process in the
culprit lesion.
In contrast, soluble CD40 ligand may be directly
involved in multiple ways in the pathophysiology of
acute coronary syndromes. Recent evidence sug-
gests that soluble CD40 ligand contributes impor-
tantly to the progression of atherosclerosis and,
consequently, to the destabilization of atheroscle-
rotic plaques
 
5,6
 
 by inducing the expression of cyto-
kines, chemokines, growth factors, matrix metal-
loproteinases, and procoagulant factors in a variety
of atheroma-associated cell types.
 
7,8,11,12,26,27
 
 Ac-
tivated platelets produce and release large amounts
of soluble CD40 ligand.
 
11
 
 A recent study demon-
strated that cardiopulmonary bypass causes an in-
crease in the plasma level of soluble CD40 ligand,
with a corresponding decrease in platelet CD40 lig-
 
* The hazard ratios are derived from the multivariate Cox proportional-hazards 
 
regression model. CI denotes confidence interval.
 
Table 2. Hazard Ratios for Death or Nonfatal Myocardial Infarction 
during Six Months of Follow-up among Patients Receiving Placebo.*
Variable Hazard Ratio (95% CI) P Value
 
Male sex 0.91 (0.68–1.39) 0.16
Age >65 yr 1.36 (0.91–1.82) 0.34
Diabetes mellitus 1.22 (0.83–1.49) 0.61
Hypercholesterolemia 0.90 (0.68–1.13) 0.59
Hypertension 1.00 (0.89–1.04) 1.00
History of coronary heart disease 0.86 (0.65–1.19) 0.72
ST-segment depression 1.04 (0.76–1.54) 0.74
Troponin T >0.1 µg per liter 2.94 (1.75–7.26) <0.001
C-reactive protein >10.0 mg per liter 2.03 (1.11–3.59) 0.02
Soluble CD40 ligand >5.0 µg per liter 2.71 (1.51–5.35) 0.001
 
Figure 4. Adjusted Hazard Ratios (Solid Squares) and 95 Percent Confidence 
Intervals (Vertical Lines) Associated with Treatment with Abciximab, as Com-
pared with Placebo, According to Quintiles of Soluble CD40 Ligand.
 
The levels of soluble CD40 ligand were as follows: first quintile, <1.93 µg per 
liter; second quintile, 1.93 to 3.50 µg per liter; third quintile, 3.51 to 5.00 µg 
per liter; fourth quintile, 5.01 to 6.30 µg per liter; and fifth quintile, more than 
6.30 µg per liter. The effect of treatment with abciximab was measured as the 
reduction in the rate of death or nonfatal myocardial infarction during six 
months of follow-up. Hazard ratios below 1.0 indicate a benefit of treatment 
with abciximab as compared with placebo. Hazard ratios have been adjusted 
for base-line characteristics.
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and content, suggesting that soluble CD40 ligand
is derived primarily from platelets and may contrib-
ute to the thrombotic complications associated with
cardiopulmonary bypass.
 
28
 
 Soluble CD40 ligand
levels correlate positively with plasma levels of sol-
uble P-selectin and urinary levels of 11-dehydro-
thromboxane B
 
2
 
.
 
29
 
 In addition, experimental studies
demonstrate that CD40 ligand is required for arte-
rial thrombus stabilization.
 
15
 
Our results provide further evidence that soluble
CD40 ligand is a marker of inflammatory throm-
botic activity. Platelet activation, as determined by
flow cytometry in patients with acute coronary syn-
dromes, correlated closely with soluble CD40 lig-
and levels (Fig. 5). These findings are supported by
the fact that inhibition of glycoprotein IIb/IIIa re-
ceptors by abciximab abrogated the increased risk
in patients with acute coronary syndromes and ele-
vated levels of soluble CD40 ligand. Thus, whereas
positivity for troponins may indicate the propensity
of the thrombus to embolize, leading to myocardial
necrosis, elevated soluble CD40 ligand levels in pa-
tients with acute coronary syndromes appear to re-
flect the inflammatory thrombotic activity of the cul-
prit lesion in recruiting and activating platelets.
In a previous subgroup analysis of data from the
CAPTURE trial, we demonstrated that additional
treatment with the glycoprotein IIb/IIIa receptor
antagonist abciximab reduced the elevated risk of
death or nonfatal myocardial infarction among tro-
ponin-positive patients to the risk level among tro-
ponin-negative patients.
 
21
 
 Such patients represent
about one third of those with acute coronary syn-
dromes.
 
1,30-33
 
 Similar findings for troponin T and
troponin I have emerged from other trials,
 
34-36
 
and measurement of troponins was subsequently
incorporated into the new guidelines as part of risk
stratification of patients with acute coronary syn-
dromes.
 
37,38
 
 Here, we demonstrate that a pro-
nounced benefit of antiplatelet therapy is also evi-
dent in patients with elevated levels of soluble
CD40 ligand. Our findings suggest that patients
with acute coronary syndromes who have elevated
levels of soluble CD40 ligand are effectively pro-
tected from adverse cardiac events by the glycopro-
tein IIb/IIIa receptor antagonist abciximab (Fig. 2
and 3).
Troponin T and soluble CD40 ligand have inde-
pendent predictive value with respect to both the
risk of ischemic events and the benefit of glycopro-
tein IIb/IIIa receptor inhibition by abciximab. Pa-
tients without evidence of myocardial injury (i.e.,
with no elevation of troponin levels), but with in-
creased soluble CD40 ligand levels, were at increased
risk for cardiovascular events and derived substan-
tial benefit from treatment with the glycoprotein
IIb/IIIa inhibitor abciximab. Accordingly, patients
at high risk for coronary thrombosis, as evidenced
by elevation of either soluble CD40 ligand or tro-
ponin T levels, who represented 54 percent of the
patients enrolled in the CAPTURE trial, derived a
marked benefit from abciximab treatment, as com-
pared with the placebo group, with an adjusted
hazard ratio for death or myocardial infarction of
0.38 (95 percent confidence interval, 0.21 to 0.72;
P<0.001) (data not shown). Thus, the measurement
of both troponins and soluble CD40 ligand, which
are separate but interacting components of the un-
derlying pathophysiological process in patients with
acute coronary syndromes, provides important in-
sights into disease activity, cardiac risk, and the ef-
fect of inhibition of glycoprotein IIb/IIIa with ab-
ciximab that are superior to those obtained with
the use of a single marker.
 
Figure 5. Correlation between the Level of Soluble CD40 Ligand and Platelet 
Activation in 161 Patients with Chest Pain.
 
Platelet activation is expressed as the percentage of monocytes that were ag-
gregated with platelets (monocyte–platelet aggregates). Dotted lines indicate 
the classification of patients into three roughly equal groups according to the 
degree of platelet activation (<15 percent, 15 to 30 percent, and >30 percent) 
and according to soluble CD40 ligand levels (<2.5 µg per liter, 2.5 to 4.5 µg per 
liter, and >4.5 µg per liter).
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